Drug General Information (ID: DDIPB1N4V2)
Drug Name			Ibritumomab tiuxetan		Drug Info		Zanubrutinib		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Antiviral Agents

Mechanism of Ibritumomab tiuxetan-Zanubrutinib Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Ibritumomab tiuxetan				Zanubrutinib
Mechanism		Risk of bleeding Antiplatelet effects				Risk of bleeding Antiplatelet/anticoagulant effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Ibritumomab tiuxetan and Zanubrutinib

Recommended Action
Management		Concomitant use of zanubrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Discontinue zanubrutinib if intracranial hemorrhage of any grade occurs.

References
1	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.